Objective There is an urgent need to assess the impact of immunosuppressive therapies on
the immunogenicity and efficacy of SARS-CoV-2 vaccination. Methods Serological and T …

Objectives Evidence suggests that B cell-depleting therapy with rituximab (RTX) affects
humoral immune response after vaccination. It remains unclear whether RTX-treated …

An attenuated humoral response to SARS-CoV-2 vaccination has been observed in some
patients with autoimmune disease, 1 2 and immunosuppressed status has been associated …

Background Disease-specific studies have reported impaired humoral responses after
SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders treated …

Background In rituximab-treated patients with rheumatoid arthritis, humoral and cellular
immune responses after two or three doses of SARS-CoV-2 vaccines are not well …

Objectives To better understand the factors that influence the humoral immune response to
vaccination against SARS-CoV-2 in patients with immune-mediated inflammatory diseases …

Objective To determine the immunogenicity of the third dose of CoronaVac vaccine in a
large population of patients with autoimmune rheumatic diseases (ARD) and the factors …

Introduction In light of the SARS-CoV-2 pandemic, protecting vulnerable groups has become
a high priority. Persons at risk of severe disease, for example, those receiving …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune responses and
infection outcomes were evaluated in 2,686 patients with varying immune-suppressive …

Objective Immunogenicity and safety following receipt of the standard SARS–CoV‐2
vaccination regimen in patients with immune‐mediated inflammatory diseases (IMIDs) are …